Hospital Universitario Virgen de las Nieves-ko ikertzaileekin lankidetzan egindako argitalpenak (28)

2022

  1. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 342-349

2021

  1. In Patients With Obesity, the Number of Adipose Tissue Mast Cells Is Significantly Lower in Subjects With Type 2 Diabetes

    Frontiers in Immunology, Vol. 12

2020

  1. Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission

    PLoS ONE, Vol. 15, Núm. 5

2019

  1. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

    PLoS ONE, Vol. 14, Núm. 8

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. Hepatotoxicity from the consumption of herbalist products by a paediatric population

    Nutricion Hospitalaria, Vol. 32, Núm. 2, pp. 652-655

2013

  1. Variation of Transaminases, HCV-RNA Levels and Th1/Th2 Cytokine Production during the Post-Partum Period in Pregnant Women with Chronic Hepatitis C

    PLoS ONE, Vol. 8, Núm. 10

2011

  1. Factors associated with hepatic steatosis in obese children and adolescents

    Journal of Pediatric Gastroenterology and Nutrition, Vol. 53, Núm. 2, pp. 196-201

  2. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin

    American Journal of Gastroenterology, Vol. 106, Núm. 7, pp. 1246-1254

2005

  1. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period

    Gastroenterology, Vol. 129, Núm. 2, pp. 512-521

2004

  1. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease

    Hepatology, Vol. 39, Núm. 6, pp. 1603-1612

2001

  1. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C

    Journal of Hepatology, Vol. 34, Núm. 5, pp. 740-747

1999

  1. Acute liver injury associated with the use of ebrotidine, a new H2- receptor antagonist

    Journal of Hepatology, Vol. 31, Núm. 4, pp. 641-646

1996

  1. Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors

    Digestive Diseases and Sciences, Vol. 41, Núm. 10, pp. 1933-1938

  2. Estudio multicentrico retrospectivo de la eficacia del interferon alfa en la hepatitis cronica C

    Medicina Clinica, Vol. 107, Núm. 18, pp. 689-692

  3. HIPOTIROIDISMO PERMANENTE TRAS TRATAMIENTO CON INTERFERON ALFA EN LA HEPATITIS CRONICA C

    Medicina Clinica

  4. Hepatitis C virus genotypes

    Gastroenterología y hepatología, Vol. 19, Núm. 5, pp. 274-280

1995

  1. Prospective study of the incidence of post-transfusion hepatitis after the exclusion of donors positive for anti-HCV ELISA 2

    Medicina clínica, Vol. 105, Núm. 17, pp. 641-644

  2. TRATAMIENTO ALTERNATIVO AL INTERFERON EN LA HEPATITIS CRONICA VIRAL

    Gastroenterologia y Hepatologia, Vol. 18, Núm. 8, pp. 430-436

1994

  1. Analysis of hepatitis B precore region in serum and liver of chronic hepatitis B virus carriers

    Journal of Hepatology, Vol. 21, Núm. 3, pp. 353-360